At the Asembia Specialty Pharmacy Summit 2017, Precision for Value’s Jorge Font spoke about his presentation with Marie Rosenthal from Specialty Pharmacy Continuum on the significant impact big employers are having in revising the approaches to specialty pharmacy benefit administration and pricing. Font shared his perspective that the real payers are, in fact, employers.
Congratulations to Precision Health Economics, and in particular the Evidence Strategy, Generation, and Communication (ESGC) practice group, for their outstanding efforts in support of the development of new legislation and FDA guidelines allowing biopharmaceutical manufacturers to more proactively share clinical and economic information with population health decision-makers on emerging therapies.
FiercePharma interviews precisioneffect’s Carolyn Morgan and Deborah Lotterman, showcasing the creative concepts behind Precision’s buzz-worthy Boston subway takeover ad campaign.
The recent AMCP presentation by Precision for Value’s Jeremy Schafer and Maureen Hennessey, “The Present and Future of Oncology Care Management” is highlighted in the latest edition of Managed Healthcare Executive.
Congratulations to PHE authors Joanna MacEwan, Jason Shafrin, and Darius Lakdawalla who, along with coauthors Felicia Forma, Ainslie Hatch, and Jean-Pierre Lindenmayer, have been awarded the 2017 JMCP Award for Excellence.
The JMCP Award for Excellence is an annual award recognizing a single article that represents the best scholarly work in managed care pharmacy. The paper, “Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed With Schizophrenia,” brings a cutting-edge statistical technique to the analysis of adherence to serious mental illness medicines.
Precision for Value president Dan Renick is interviewed for Pharmaceutical Commerce, providing his in-depth perspective on today’s payer and provider markets.
In a new article for Clinical Leader, PHE’s Ross Maclean and Jeroen Jansen explain how evidence synthesis can reduce the guesswork of clinical trial design.
A large manufacturer client was preparing to launch a biosimilar into a highly competitive and complex market. In this case study, the brand team sought to learn how payers would view the product in relation to key competitors, understand decision drivers and thresholds, and identify potential competitive reactions resulting from any actions taken.
Learn how one pharmaceutical manufacturer overcame inconsistencies in tracking payer coverage and performance across the organization. With the application of a Payer Plan Hierarchy, the client was able to better understand the payer landscape and had a more direct and consistent line of sight on supporting product performance in managed markets contexts.
Precision for Value’s Jeremy Schafer comments on pricing and reimbursement of dupilumab, Sanofi/Regeneron’s first atopic dermatitis biologic, in BioPharm Insight.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
